Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP-sensitive potassium channel subunit SUR2 is a regulatory subunit of KATP channels, part of the ATP-binding cassette (ABC) transporter C family. It exists mainly as two splice variants, SUR2A (predominantly cardiac) and SUR2B (predominantly smooth muscle), and co-assembles with Kir6.x (Kir6.1 or Kir6.2) pore-forming subunits to form functional KATP channels. SUR2 senses intracellular nucleotides (Mg-ADP, Mg-ATP) and pharmacologic ligands, linking cellular metabolic state to membrane excitability. SUR2-based KATP channels play fundamental roles in cardiovascular homeostasis, stress response (e.g., ischemic preconditioning), and muscle function. Targeting SUR2 is therapeutically relevant for cardiovascular disorders, certain metabolic and muscular conditions, and as a secondary target for some antidiabetic drugs.
Channel inhibition: Sulfonylureas bind SUR2 and inhibit KATP channel activity, leading to cell membrane depolarization and downstream effects Channel activation: KATP openers bind SUR2, increasing channel opening, hyperpolarizing membranes, and reducing cellular excitability
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-sensitive potassium channel subunit SUR2 (SUR2).